Clinical-stage biopharmaceutical company developing peptide-based therapeutics for gastrointestinal diseases.
Protagonist Therapeutics, Inc., a dynamic biopharmaceutical firm headquartered in Newark, California, specializes in the discovery and development of peptide-based therapeutic drugs targeting hematology, blood disorders, inflammatory diseases, and immunomodulatory conditions. The company's innovative pipeline includes rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials. Rusfertide shows promise for treating polycythemia vera, hereditary hemochromatosis, and other blood-related disorders.
Founded in 2006, Protagonist Therapeutics is advancing PN-943, an oral alpha-4-beta-7 integrin-specific antagonist peptide, through Phase II trials for the treatment of inflammatory bowel disease (IBD). Additionally, the company is developing PN-235, an orally delivered interleukin-23 receptor-specific antagonist targeting both IBD and non-IBD indications. These innovative therapies reflect Protagonist Therapeutics' commitment to addressing critical unmet medical needs through cutting-edge peptide technology.
Protagonist Therapeutics operates under a collaborative framework, exemplified by its strategic partnership with Janssen Biotech, Inc., enhancing its capabilities in research, development, and commercialization. This collaboration underscores Protagonist Therapeutics' dedication to leveraging strategic alliances to advance novel therapeutic solutions.
With a strong focus on scientific rigor and innovation, Protagonist Therapeutics continues to expand its footprint in the biopharmaceutical industry. By pushing the boundaries of peptide-based drug development and fostering collaborative partnerships, the company aims to deliver transformative therapies that improve outcomes for patients worldwide.